Drugs / TAK-280
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05220098 | Apr 2022 → Jul 2025 | cancer of unknown primary site | Takeda | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05220098 ↗ |
| Route | Intravenous | “TAK-280 as IV infusion” NCT05220098 ↗ |